Boxer Capital Management’s AN2 Therapeutics ANTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ANTX
ACA
Boxer Capital Management's ANTX Position: Q3 2026 in Review
Boxer Capital Management increased its AN2 Therapeutics (ANTX) stake by 26% in Q3 2026, buying an estimated $1.03M and bringing the position to 944,035 shares worth $5.02M. The position accounts for 0.44% of the portfolio, ranked #30.
Boxer Capital Management first reported a position in ANTX in Q1 2026 and has held it in 3 quarters since. 88 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.
- Boxer Capital Management held 944,035 shares of AN2 Therapeutics worth $5.02M as of Q3 2026.
- Boxer Capital Management bought 195,000 AN2 Therapeutics shares in Q3 2026, an estimated $1.03M.
- AN2 Therapeutics made up 0.44% of Boxer Capital Management's portfolio in Q3 2026, its #30 holding.
- Boxer Capital Management first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 88 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.
Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.